PY
PYC Therapeutics Limited
PYC.AX · ASX
$2.44 -2.60% (-$0.07)
1M +20.10%
Market Cap $1.46B
P/E Ratio -
Div. Yield -
ROE 16.27%
Bulios Fair Price
$1.45
40.5% downside
Current Price
$2.44
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PYC.AX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
85 /100
Cheap P/B 2.10x
P/FFO N/A
P/S N/A
Growth
100 /100
Growing Book val. growth 192.34%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 16.27%
ROA 6.12%
Asset turnover 0.00x
Debt
69 /100
Low Current ratio 33.48x
Int. coverage -2,043.25x
Debt/Equity 0.00x
Stability
20 /100
Unstable Rev. volatility 72.93%
EPS volatility 546.12%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PYC.AX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Rohan Hockings
Employees
37
Headquarters
Nedlands
Upcoming events
01 MAR
Earnings
Upcoming earnings report